Earnings Feed
Start Free
BIO-TECHNE Corp·4

May 7, 5:24 PM ET

Bohnen Shane 4

4 · BIO-TECHNE Corp · Filed May 7, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne (TECH) SVP Shane Bohnen Exercises Options, Sells Shares

What Happened
Shane Bohnen, SVP and General Counsel of Bio-Techne (TECH), exercised options to acquire 8,400 shares on 2026-05-05. The exercise price was $47.60 per share (cost = $399,840). To cover taxes/exercise obligations, 7,055 of the acquired shares were surrendered/withheld at a market price of $56.68 per share (value = $399,877). After the sell-to-cover withholding, Bohnen received a net 1,345 shares. The filing shows this as an option exercise (code M) with tax withholding/surrender (code F).

Key Details

  • Transaction date: 2026-05-05; Form 4 filed 2026-05-07 (timely).
  • Option exercise: 8,400 shares acquired at $47.60 each (total $399,840).
  • Withholding/tax surrender: 7,055 shares withheld/disposed at $56.68 each (value $399,877).
  • Net shares issued to insider: 1,345 shares (8,400 − 7,055).
  • Notable footnote: F1 — the options exercised were fully exercisable. Other footnotes in the filing describe vesting schedules for other awards but do not change this exercise.
  • Shares owned after the transaction: not specified in the excerpt provided.

Context
This was a cashless/sell-to-cover option exercise: the insider exercised options and surrendered most of the resulting shares to satisfy exercise price and tax withholding rather than paying cash. Such transactions are common for option exercises and are generally routine administrative actions rather than an explicit buy or sell market opinion. Transaction codes: M = option exercise/conversion; F = payment of exercise price or tax liability.

Insider Transaction Report

Form 4
Period: 2026-05-05
BIO-TECHNE CorpTECH
Bohnen Shane
SVP - General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    2026-05-05$47.60/sh+8,400$399,840→ 14,304 total
  • Tax Payment

    Common Stock

    2026-05-05$56.68/sh−7,055$399,877→ 7,249 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1]
    2026-05-05−8,400→ 448 total
    Exercise: $47.60Exp: 2026-08-07→ Common Stock (8,400 underlying)
Holdings

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $66.97Exp: 2027-08-05→ Common Stock (8,944 underlying)
    8,944

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $120.46Exp: 2028-08-06→ Common Stock (3,460 underlying)
    3,460

  • Stock Option (Right to Buy)

    [F2]
    Exercise: $94.52Exp: 2029-08-15→ Common Stock (3,508 underlying)
    3,508

  • Stock Option (Right to Buy)

    [F3]
    Exercise: $73.76Exp: 2030-04-03→ Common Stock (3,928 underlying)
    3,928

  • Stock Option (Right to Buy)

    [F5]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (16,302 underlying)
    16,302

  • Restricted Stock Units

    [F4][F6]
    → Common Stock (49 underlying)
    49

  • Performance Restricted Stock Units

    [F4][F7]
    → Common Stock (4,802 underlying)
    4,802

  • Performance Stock Option (Right to Buy)

    [F7]
    Exercise: $84.61→ Common Stock (12,924 underlying)
    12,924

  • Performance Restricted Stock Units

    [F4][F8]
    → Common Stock (10,012 underlying)
    10,012

  • Restricted Stock Units

    [F4][F9]
    → Common Stock (3,338 underlying)
    3,338

  • Stock Option (Right to Buy)

    [F10]
    Exercise: $74.91Exp: 2034-08-15→ Common Stock (13,488 underlying)
    13,488

  • Performance Restricted Stock Units

    [F4][F11]
    → Common Stock (13,992 underlying)
    13,992

  • Restricted Stock Units

    [F4][F12]
    → Common Stock (6,996 underlying)
    6,996

  • Stock Option (Right to Buy)

    [F13]
    Exercise: $53.60Exp: 2035-08-15→ Common Stock (17,897 underlying)
    17,897
Footnotes (13)
  • [F1]Fully exercisable.
  • [F10]Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F11]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F12]2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F13]Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
  • [F2]Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.
  • [F3]Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F5]Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
  • [F6]49 restricted stock units vest on 8/15/2026.
  • [F7]Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F8]Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F9]1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
Signature
/s/ Andrew Nick as Attorney-in-Fact for Shane Bohnen pursuant to Power of Attorney previously filed.|2026-05-07

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES